Translate

dedanlenfritruestr

Literatur

Literaturliste

  1. Paul Gottlieb Werlhof (1699-1767). Thrombocytopenic purpura (Editorial). JAMA 1968;206:2892
  2. Dameshek W, Miller EB. The megakaryocytes in idiopathic thrombocytopenic purpura. A form of hypersplenism. Blood 1946;1:27- 51
  3. Doan CA, Bouroncle BA, Wiseman BK. Idiopathic and secondary thrombocytopenic purpura: clinical study and evaluation of 381 cases over a period of 28 years. Ann Intern Med 1960;53:861-76
  4. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909-13
  5. DiFino SM, Lachant NA, Kirshner JJ, Gottlieb AJ. Adult idiopathic thrombocytopenic purpura. Clinical findings and response to therapy. Am J Med 1980;69:430-42
  6. Dodds WJ, Wilkins RJ. Animal model: canine and equine immune-mediated thrombocytopenia and idiopathic thrombocytpenic purpura. Am J Pathol 1977;86:489-91
  7. Foster CB, Choi EH, Zhu S, Lehrnbecher T, Imbach P, Kuhne T, Chanock SJ. Polymorphisms within inflammatory cytokines and Fcg receptors are associated with chronic immune thrombocytopenia purpura. Blood 1999;94 (Suppl. 1):679a
  8. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951;38:1-10
  9. Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann NY Acad Sci 1965;124:499-542
  10. McFarland JG, Collins J, Aster RH, Moghaddam M, Bussel J. Evaluation of a platelet glycoprotein (GP) specific assay in the diagnosis of autoimmune thrombocytopenia. Blood 1999;94 (Suppl. 1):15a
  11. Nugent D, Nakagawa P. Platelet CD40L (CD40 ligand) is a major target antigen in immune mediated thrombocytopenia. Blood 1998;92 (Suppl. 1):176a
  12. Barrett JC, Call SA, Arndt DW, Dudley KA, Mahan JA, Saleh MN. Thrombocytopenia with platelet-associated IgM antibodies: patient characteristics and responsiveness to ITP therapy. Blood 1998;92 (Suppl. 1):82b
  13. Bettaieb A, Oksenhendler E, Duedari N, Bierling P. Cross-reactive antibodies between HIV-gp120 and platelet GP IIIa (CD61) in HIV-related imune thrombocytopenic purpura. Clin Exp Immunol 1996;103:19-23
  14. Lozano ML, Curtis BR, Hansen RM, Bayliss K, Petersen JA, Aster RH. A GP IIb/IIIa-specific autoantibody from a patient with acquired amegakaryocytic thrombocytopenia appears to be the first example of a human ligand mimetic immunoglobulin. Blood 1998;92 (Suppl. 1):175a
  15. Chang M, Nakagawa PA, Schwartz M, Dadfalza V, Williams SA, Buzby JS, Zhu E, Lam A, Nugent DJ. Effects of immune thrombocytopenic purpura (ITP) patient plasma on in vitro megakaryocytopoiesis. Blood 1999;94 (Suppl. 1): 646a
  16. Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony fomration and proplatelet formation. Blood 1999;93:1951-8
  17. Ballem PJ, Segal GM, Stratton J, Gernsheimer T, Adamson JW, Slichter SJ. Mechanism of thrombocytopenia in chronic autoimmune thormbocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987;80:33-40
  18. Karpatkin S, Charmatz A. Heterogeneity of human platelets. I. Metabolic and kinetic evidence suggestive of young and old platelet. J Clin Invest 1969;48:1073-82
  19. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40
  20. Cohen YC, Djulbegovic B, Shamai-Lubovitz I, Mozes B. The natural history of severe idiopathic thormbocytopenic purpura. Blood 1998;92 (Suppl. 1):177a
  21. Renaudier Ph, Beley O, Adeleine P, Treille-Ritouet D, Fiere D. Diagnosis of idiopathic thrombopenic purpura (ITP): application of the ASHs guideline in 308 adult patients. Blood 1998;92 (Suppl. 1):88b
  22. Ben-Yehuda D, Gillis S, Eldor A and the Israeli ITP Study Group. Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Acta Haematol 1994;91:1-6
  23. von dem Borne AEGKr, Helmerhorst FM, Leeuwen EF. Autoimmune thrombocytopenia: detection of platlet autoantibodies with a suspension immunofluorescence Test. Br J Haematol 1980;45:319-27
  24. George J. Platelet immunoglobulin G: its significance for the evaluation of thrombocytopenia and for understanding the orign of alpha-granule proteins. Blood 1990;76:859-70
  25. Shulman NR, Leissinger CA, Hotchkiss AJ, Kautz JA. The nonspecific nature of platelet-associated IgG. Trans Assoc Am Phys 1982;95:213-20
  26. Kiefel V, Santoso S, Weisheit M. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet reactive antibodies. Blood 1984;70:1722-6
  27. Tomer A, Kasey S. Autoimmune thrombocytopenia: determination of circulating autoantibodies against platelet specific receptors using flow cytometry. Blood 1998;92 (Suppl. 1):90b
  28. Gustin D, Warren T, Buntinas R. Idiopathic thrombocytopenic purpura the utility of the bone marrow examination in adults. Blood 1998;92 (Suppl. 1):176a
  29. Jubelirer SJ, Harpold RM. Is the bone marrow examination justified in idiopathic (or immune) thrombocytopenic purpura (ITP) in adults. Blood 1998;92 (Suppl. 1):86b
  30. Koike Y, Yoneyama A, Shirai J, Ishida T, Shoda E, Miyazaki K, Sunaga S, Horie R, Aoki K, Koike K, Ogata I, Tahara T, Kato T, Nakahara K, Kariya T, Higashihara M. Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. Thromb Haemost 1998;79:1106-10
  31. Porcelijn L, Folman C. The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb Haemost 1998;79:1101-5
  32. Berkman N, Michaeli Y, Or R, Eldor A. EDTA-dependent pseudothrombocytopenia: a clinical study of 18 patients and a review of the literature. Am J Hematol 1991;36:195-201
  33. Peterson LC, Rao KV, Crosson JT, White JG. Fechtner syndrome – a variant of Alports syndrome with leukocyte inclusions and macrothrombocytopenia. Blood 1985;65:397-406
  34. Greinacher A, Nieuwenhuis HK, White JG. Sebastian platelet syndrome: a new variant of hereditary macrothrombocytopenia with leukocyte inclusions. Blut 1990;61:282-8
  35. Jantunen E. Inherited giant platelet disorders. Eur J Haematol 1994;53:191-6
  36. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J. Pediatr. 1994;125: 876-85
  37. Greinacher A. Seltene hereditäre Thromobzytopenien und Thrombozytopathien. In: Müller-Berghaus G, Pötzsch B (Hrsg.): Hämostaseologie. Springer Verlag 1998, S.72-82
  38. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thormbocytopenia. N Engl J Med 1993;329:1463-6
  39. Rath W. Das HELLP-Syndrom - eine interdisziplinäre Herausforderung. Deutsch Ärztebl 1998;95:A-2997-3002
  40. Bussel J, Kaplan C. The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. Baillière's Clinical Haematology 1998;11:391-80
  41. Mueller-Eckhardt C, Kiefel V, Grubert A, Grubert A, Kroll H, Weisheit M, Schmidt S, Mueller-Eckhardt G, Santoso S. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989;1:363-6
  42. George JN, Berkowitz SD, Raksob GE. Platelets: acute thrombocytopenia. American Society of Hematology Education Program Book. Dec. 1998:371-83
  43. Bednar B, Cook JJ, Holahan MA, Cunningham ME, Jumes PA, Bednar RA, Hartman GD, Gould RJ (Merck Research). Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood 1999;94:587-99
  44. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 (abciximab) therapy. Circulation 1997;95:809-13
  45. Greinacher A. Heparin-induzierte Thrombozytopenia – Pathogenese und Behandlung. Hämostaseologie 1999;19:1-12
  46. Yang C, Xia Y, Li J, Kuter DJ. The appearance of anti-thrombopoietin antibody and circulating thrombopoietin-IgG complexes in a pateints developint thrombocytopenia after injection of PEG-rHuMGDF. Blood 1999;94 (Suppl. 1):681a
  47. Cavalli F. Rare syndromes in Hodgkin's disease. Ann Oncol 1998;9 (Suppl.5):S109-S113
  48. Choufi B, Tournilhac O, Cure H, Brahimi S, Eychenne D, By J, Fleury J, plagne R, Travade P. Immune thrombocytopenic purpura in Hodgkin's disease. Blood 1999;94 (Suppl. 1):244b
  49. Strupp C, Dietze L, Gattermann N, Germing U, Meckenstock G, Aul C. Severe autoimmune thrombocytopenia after fludarabine tratment in two patients with CLL. 1996;Onkolgie 1999;22 (Suppl. 1):55
  50. Otton SH, Turner DL, Frewin R, Cavies SV, Johnson SA. Autoimmune thrombocytopenia after treatment with campath 1H in a patient with chronic lymphocytic leukaemia. Brit J Haematol 1999;109: 261-2
  51. Johnston PB, Inwards DJ. Rituximab-associated immune thrombocytopenic purpura. Blood 1999;94 (Suppl. 1):263b
  52. Verwey J, Breed WPM, Hilen HFP. Bleomycin-induced early-onset transient decrease in platelet counts. Neth J Med 1984;27:202-5
  53. Balfour HH Jr. Antiviral drugs. N Engl J Med 1999;340:1255-68
  54. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962;266:905
  55. Beutler E. Platelet transfusion: the 20,000/m L trigger. Blood 1993;81:1411-3
  56. Slichter SJ, LeBlanc R, Jones MK, Townsend-McCall D, Bolgiano D, Gernsheimer T, Nichol J, Stead R. Quantitative analysis of bleeding risk in cancer patients prophylactically transfused at platelet counts of 5,000, 10,000, or 20,0000 plts/m l. Blood 1999;94 (Suppl. 1):376a
  57. Bolton-Mages PHB, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura (ITP) - assessment of UK practice against published guidelines. Lancet 1997;350:620-3
  58. Bussel JB. Management of children with ITP at diagnosis: consensus and controversy. Blood 1999;94 (Suppl. 1):78b
  59. Sutor AH. Acute autoimmunothrombocytopenia in childhood. Are we treating the platelet count. Semin Thromb Hemost 1998;24:545-8.
  60. Lilleyman JS. Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Archives of Diseaes of Childhood 1994;71:251-3
  61. Diaz L, Feliu A, Sciuccati G, Bonduel M. Immune thrombocytopenic purpura (ITP) in childhood. Blood 1998;92 (Suppl. 1):83b
  62. Salama A, Huhn D. Thrombozytentransfusion. Onkologie 1998;4:185-90
  63. Weisberger AS, Suhrland LG. Massive corticosteroid therapy in the management of resistant thrombocytopenic purpura. Am J Med Sci 1958; 236:425-33
  64. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994;330:1560-4
  65. Warner M, Wasi P, Couban S, Hayward C, Warkentin T, Kelton JG. Failure of pulse high-dose desamethasone in chronic idiopathic immune thrombocytopenia. Am J Hematol 1997;54:267-70
  66. Gillis S, Eldor A. Immune thrombocytopneic purpura in adults: clinical aspects. Baillière's Clinical Hematology 1998;11:361-72
  67. Schiavotto C, Ruggeri M, Rodeghiero F. Failure of repeated courses of high-dose intravenous immunoglobulin to induce stable remission in patients with chronic idiopathic thrombocytopenic purpura. Ann Hematol 1995;70:89-90
  68. Baumann MA, Menitove JE, Aster RH, Anderson T. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med 1986;104:808-9
  69. Kattamis J, Shankar S, Cohen AR. Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin. J Pediatr 1997;130:281-3
  70. Moser AM, Shalev H, Kapelushnik J. A very early respsonse with intravenous anti-D treatment for childhood acute ITP. Blood 1999,94 (Suppl. 1):82b
  71. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 1991;77:1884-93
  72. Laber DA, Rice L. Anti-D immune globulin can precipitate severe hemolysis in immune thrombocytopenic purpura (ITP) patients with occult Evan's syndrome. Blood 1999;94 (Suppl. 1):81b
  73. Semple JW, Allen D, Hogarth M, Freedman J, Blanchette V, Butchart S, Wakefiled C, Carcao M. In vivo actions of anti-d in children with chronic autoimmune thrombocytopenic purpura. (AITP). Blood 1998;92 (Suppl. 1):178a
  74. Schilling RF. Estimating the risk for sepsis after splenectom in hereditary spherocytosis. Ann Intern Med 1995;122:187-8
  75. Vianelli N, Valdrè L, Fiacchini M, deVivo A, Catani L, Gogliotta L, Trabacchi E. Long-term follow-up in idiopathic thrombocytopenic purpura (ITP): single center experience of 310 patients. Blood 1999;94 (Suppl. 1):19a
  76. Rovó A, Penchasky D, Korin J, Santos I, Celebrín L, Rosenfeld E. Splenectomy in idiopathic thrombocytopenic purpura (ITP). Effective, yes, but for how long. Blood 1998;92 (Suppl. 1):177a
  77. Tarantino MD, McFall RE. Immune thrombocytopenic purpura (ITP) in children: outcome after treatment with ivIG, anti-D and splenectomy. Blood 1999;94 (Suppl. 1):19a
  78. Facon T, Caulier MT, Fenaux P, Plantier I, Marchandise X, Ribet M, Jouet JP, Bauters F. Accessory spleen in recurrent chronic immune thrombocytopenic purpura. Am J Hematol 1992;41:184-9
  79. Heyns AD, Lotter MG, Badenhorst PN, de Kock F, Pieters H, Herbst C, van Reenen OR, Kotze H, Minnaar PC. Kinetics and sites of destruction of 111-Indium-oxine-labeled platelets in idiopathic thormbocytopenic purpura: a quantitative study. Am J Hematol 1982;12:167-77
  80. Stasi R, Stipa E, Masi M, Cecconi M, Scimo MT, Oliva F, Sciarra A, Perrotti AP, Adomo G, Amadori S. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436-42
  81. Law C, Marcaccio M, Tam P, Heddle N, Kelton JG. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med 1997,336:1494-8
  82. Fenaux P, Caulier MT, Hirschauer C, Beuscart R, Goudemand J, Bauters F. Reevaluation of the prognositc factors for splenectomy in chronic idiopathic thrombocytopenic purura. Eur J Haematol 1989;42:259-64
  83. Tsiotos G, Schlinkert RT. Laparoscopic splenectom for immune thrombocytopenic purpura. Arch Surge 1997;132:642-6
  84. Watson DI, Coventry BJ, Chin T, Gill PG, Malycha P. Laparoscopic versus open splenectomy for immune thrombocytopenic purpura. Surgery 1997;121:18-22
  85. Calverley DC, Jones GW, Kelton JG. Splenic radiation for corticosteroid-resistant immune thrombocytopenia. Ann Intern Med 1992;116:977-81
  86. Baumann MA, Menitove JE, Aster RH, Anderson T. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med 1986;104:808-9
  87. Kelton JG, McDonald JWD, Barr RM, Walker I, Nicholson W, Neame PB, Hamid C, Wong TY, Hirsh J. The reversible binding of vinblastine to platelets: implications for therapy. Blood 1981;57:431-8
  88. Nenci GG, Agnelli G, De Cunto M, Gresele P. Infusion of vincristine-loaded platelets in acute ITP refractory to steroids: an alternative to splenectomy. Acta Haematol 1981;66:117-21
  89. Ahn YS, Byrnes JJ, Harrington WJ, Cayer ML, Smith DS, Brunskill DE, Pall LM. The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets. N Engl J Med 1978;298:1101-7
  90. Snyder HW, Cochran SK, Balint JP Jr, Bertram JH, Mittelman A, Guthrie TH Jr, Jones FR. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood 1992;79:2237-45
  91. Knöbl P, Derfler K. Immunologisch bedingte hämatologische und hämostaseologische Erkrankungen. Indikationen für die Immunadsorption. In: Brunkhorst R, Koch KM, Koll T (Hrsg.): Klinische Immunadsorption. Wissenschaftliche Verlagsgesellschaft Stuttgart, 1999, S. 53-67
  92. Richter WO, Donner MG, Selmaier A, Hiller E, Schwandt P. Efficacy and safety of immunoglobulin apheresis. ASAIO J 1997;43:53-9
  93. Meran JG, Freund M, Kessen-Albers M, Ganser A, Ludwig H. Cyclosporin A (CsA) in steroid-refractory, chronic idiopathic immune-thrombocytopenia. Onkologie 1999;22(Suppl. 1):121
  94. Fibich C, Fiedler F, Herold M, Kegel T, Schöber C, Schmoll HJ. Mycophenolate-mofetil (Cellceptâ , MMF) in the treatment of steroid-refractory autoimmune thrombocytopenia and Evans-syndrome. Blood 1998;92 (Suppl. 1):177a
  95. Mey U, Kleinschmidt R, Sauerbruch T, Schmidt-Wolf IGH. Cyclophosphamide pulse therapy in refractory idiopathic thrombocytopenic purpura. Onkologie 1999;22(Suppl. 1):125
  96. Mannuccio Mannucci P. Hemostatic Drugs. N Engl J Med 1998;339:245-253
  97. Gururangan S, Bussel JB. Combination immunotherapy for patients wtih refractory ITP or Evan's syndrome (ES). Blood 1998;92 (Suppl. 1):84b
  98. Huhn RD, Read EJ, Rick M, Leitman SF, Kimball J. Gratwohl A, Young NS, Barrett AJ, Dunbar CE. Intensive immunosuppression with high-dose cyclophosphamide and autologous CD34+ selected hematopoietic cell support for chronic refractory autoimmune thrombocytopenia (interim report). Blood 1998;92 (Suppl. 1):178a
  99. Nakamura R, Huhn RD, Read EJ, Rick M, Leitman SF, Greene A, Gratwohl A, Young NS, Barrett AJ, Dunbar CE. Intensive immunosuppression with high-dose cyclophosphamide and autologous CD34+ selected hematopoietic cell support for chronic refractory autoimmune thrombocytopenia (AITP): interim report. Blood 1999;94 (Suppl. 1): 646a
  100. Hurtado RM, Myrna CH, Silmia CM, Juan SM, Juan OC, Manuel BR, Carolina GG, Pablo VV, Miguel PJ, Arturo L, Martha K. Autologous stem cell transplantation for autoimmune disorders a case report. Blood 1999;94 (Suppl. 1):401b
  101. Miranda M, Reich L, Traynor A, Young J, papadopoulas E, Fishman M, Welles C, Burt RK. Cure of Evans syndrome (autoimmune hemolytic anemia and idiopathic thrombotic thrombocytopenia) by allogeneic hematopoietic stem cell transplantation. Blood 1999;94 (Suppl. 1):384b
  102. Schneider P, Chemnitz J, Hünerlitürkoglu A, Gattermann N, Söhngen D, Haas R. Randomized multicenter study for the treatment of adult idiopathic thrombocytopenic purpura. Onkologie 1999;22 (Suppl. 1):124
  103. de Groot Ph G, Wu YP, Sixma JJ, Harris R, Middleton S. Fibrinogen coated albumin microcapsules as a platelet substitute. Mechanism of action in human thrombocytopenic blood. Blood 1998;92 (Suppl. 1):182a
  104. Alemany M, Hernandez MR, Bozzo J, Galan AM, Reverter JC, Mazzara R, Ordinas A, Escolar G. In vitro evaluation of the hemostatic effectiveness of non viable platelet preparations: stuides with frozen-thawed, sonicated or lyophilized platelets. Vox Sang 1997;73:36-42
  105. George J, Raskob G, Lichtin A, Bussel J, Cobos E, Green D, Malone R, Rutherford C, Wasser J, TenHoor C, Nadeau K. Safety and effect on platelet count of single-dose monoclonal antibody to CD40 ligand (ANTOVAÔ ) in patients with chronic ITP. Blood 1998;92 (Suppl. 1):707a
  106. Bussel J, Wissert M, Oates B, Scaramucci J, Nadeau K, Adelman B. Humanized monoclonal anti-CD40 ligand antibody (hu5c8) rescue therapy of 15 adults with severe chroninc refractory ITP. Blood 1999;94 (Suppl. 1):646a
  107. George J, Raskob G, Bussel J, Cobos E, Green D, Tongol J, Rutherford C, Wasser J, Croft H, Rhinehart S, Oates B, Scaramucci J, Nadeau K. Safety and effect on platelet count of repeated doses of monoclonal antibody to CD40 ligand in patients with chronic ITP. Blood 1999;94 (Suppl. 1):19a
  108. Bussel JB, pers. Mitteilung. 12/1999
  109. Ericson SG, Coleman KD, Wardwell K, Baker S, FAnger MW, Guyre PM, Ely P. Monoclonal antibody 197 (anti-FcgRI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of FcgRI on circulating monocytes. Br J Haematol 1996;92:718-24
  110. Perotta A, Sunneberg TA, Scott J, Ratanatharaphorn V, Hook C, Attas L Dason D, Kunkel LA. Rituxan® in the treatment of chronic idiopathic thrombocytopenia purpura (ITP). Blood 1999;94 (Suppl. 1):14a
  111. Perrotta AL, Abuel C. Update of response to rituximab of chronic relapsing ITP. Blood 1999;94 (Suppl. 1):82b
  112. Emmons RBV, Reid DM Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068-71
  113. Shibuya K, Akahori H, Tahara E, Kato T, Miyazaki H. Pegylated recombinant human megakaryocyte growth and development factor effectively improves thrombocytopenia in a murine model of idiopathic thrombocytopenic purpura, (NZW x BXSB)F1. Blood 1998;92 (Suppl. 1):376a
  114. Bussel JB. Immune thrombocytopenia in pregnancy and alloimmune. J Reprod Immunol 1997;37:35-61
  115. Christiaens GCML. Immune thrombocytopenic purpura in pregnancy. Baillière's Clinical Haematology 1998;11:373-80